Harrow, Inc.

Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025Cash of €19.7 million on September 30, 2024, including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced on October 14, 2024The Company estimates that it is financed into Q3 2025 October 17, 2024 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the revenue and cash position for Nicox SA and its subsidiaries (the “Nicox Group”) for the third quarter of 2024 and financial results for Nicox SA (the “Company”) for the first half of 2024, as approved by the Board of Directors on October 16, 2024 and provided an update on key future milestones. As previously announced, the Company is no longer reporting consolidated accounts under IFRS standards and figures communicated for the Nicox Group are for information only. “The first 9 months of 2024 have been a period of significant strategic progress for Nicox, in which we have stabilized our financial situation with a royalty sale, optimised our cost structure to focus on our lead asset and partnerships, renewed the Board of Directors and increased our institutional shareholder base through targeted financing activities. Our development team has also continued driving the NCX 470 Denali clinical trial with the completion of recruitment in the United States in July, and the target date for topline results now advanced to Q3 2025.” said Gavin Spencer, Chief Executive Officer of Nicox. “We have also seen major progress in our partnership activity, with our Chinese licensee Ocumension Therapeutics obtaining approval for ZERVIATE in China, where we are now awaiting the commercial launch, and the signature of a new research agreement, including a pre-agreed license option, for NCX 1728 with leading ophthalmic pharmaceutical and medical technology company Glaukos. Going forward we will be focussing on the completion of the Denali trial and partnerships for the commercialisation of NCX 470 in the United States and elsewhere.” Key Future Milestones Launch of ZERVIATE in China by Nicox’s partner, Ocumension Therapeutics: Approval obtained in September 2024. Whistler Phase 3b clinical trial, initiated in December 2023, investigating NCX 470’s dual mechanism of action (nitric oxide and prostaglandin analog) in intraocular pressure lowering: results are currently expected in the first quarter of 2025. Denali Phase 3 clinical trial evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension: recruitment of the last patient in the U.S. in the Denali trial was in July when overall recruitment was approaching the 95% level, with recruitment continuing in China and topline results are expected in Q3 2025. Management ChangeEmmet Purtill, Vice President of Business Development at Nicox, has joined the Executive Committee. Emmet has been with the company since 2006 and has played a significant role in establishing our partnerships, notably the relationships with Ocumension and Kowa, and had led many of our recent deals. Emmet joins Sandrine Gestin, VP Finance and HR, Doug Hubatsch, Chief Scientific Officer and Gavin Spencer, Chief Executive Officer, who are the other Executive Committee members.Revenue, Cash Position for the Nicox Group for the Third Quarter 2024 and post-period events Due to the sale of the VYZULTA royalty, the Nicox Group received no material revenue in the third quarter of 2024 compared to €1.8 million (net revenue1 €1.1 million, entirely composed of net royalties) for the first quarter 2023.$16.5 million Royalty and Equity Financing with Soleus announced on October 14, 2024.Cash of €19.7 million at 30 September 2024 including the estimated net proceeds from the VYZULTA royalty sale and accompanying investment mentioned above, after deduction of legal, banking and other fees, compared to €7.7 million at 30 June 2024. Based on this cash position, expected milestone income from existing agreements, and accounting for the €5.2 million debt repayments by June 2025, the Company estimates that it is financed into Q3 2025. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company. The Company cannot guarantee that it is financed to the topline results of the Denali trial, and completion of the Denali clinical trial may require additional financing.As of September 30, 2024, the Nicox Group had financial debt of €20.4 million (entirely held by Nicox SA), consisting of €19.4 million in the form of a bond financing agreement with Kreos Capital (an affiliate of BlackRock), and a €1.0 million credit agreement guaranteed by the French State, and granted in the context of the COVID-19 pandemic. Nicox will be repaying €5.2 million of the Kreos Capital debt by June 2025.The Company continues to evaluate all options for non-dilutive and dilutive financing to extend its cash runway. In particular the Company is actively exploring multiple strategic options which could facilitate the development and commercialization of its product candidate NCX 470 and the future growth of the Company. First Half 2024 Financial Results for Nicox SA Net revenue1 for the first half of 2024 was €4.9 million (including €1.7 million of net royalty payments and a license payment of €3.0 million) versus €1.7 million (consisting entirely of net royalty payments) for the first half of 2023. Operating expenses for the first half of 2024 were €10.1 million compared to €14.8 million for the first half of 2023. The decrease in operating expenses for the first half of 2024 compared with the first half of 2023 is explained by the costs related to the finalization of the Mont-Blanc study which had an impact on the first half of 2023. In addition, operating expenses for the first half of 2023 included a €3.5 million adjustment relating to the rebilling of services performed in 2022 by the U.S. subsidiary.Net loss for the six months ended June 30, 2024, was €4.4 million, compared to a net loss of €12.5 million for the same period in 2023. The reduction in the net loss for the first half of 2024 is mainly due to the increase in revenues following the signature of the agreement with Kowa for Japan for which the Company has received an initial payment of €3 million, and to the reduction in operating expenses as explained above.As of June 30, 2024, Nicox SA had cash and cash equivalents of €7.7 million as compared with €11.3 million as of December 31, 2023. Including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced on October 14, 2024 and exclusively on the basis of the development of NCX 470, the Company estimates it is currently funded into Q3 2025. As of June 30, 2024, Nicox SA had financial debt of €20.5 million, consisting of (i) €19.4 million in the form of a bond financing agreement with Kreos Capital signed in January 2019 and (ii) a €1.1 million credit agreement guaranteed by the French State, and granted in August 2020 in the context of the COVID-19 pandemic.Only the figure related to the cash position and the debt of Nicox SA as of December 31, 2023, is audited; all other figures in this press release are non-audited. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. . Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Income Statement (in thousands of euros) June 30, 2024June 30, 2023Sales of services – Various re-invoicing 23Royalties for patent grants 6 0672 721REVENUE 6 0692 724Reversals of depreciation, amortization, provisions and transfers of expenses 4497Other income 10577TOTAL OPERATING INCOME 6 6232 807Other purchases and external charges (6 853)(12 049)Taxes, duties and similar payments (42)(63)Salaries and wages (1 548)(918)Social security expenses (412)(361)Amortization (9)(11)Provisions for liability and charges -(108)Other expenses (1 190)(1 189)Exchange loss on receivables and debts (57)(130)TOTAL OPERATING EXPENSES (10 111)(14 829) OPERATING PROFIT (LOSS) (3 488)(12 022)Other interest and similar income 398550Reversal of provisions, impairment losses and transfer of expenses 1339Foreign exchange gains 23110TOTAL FINANCIAL INCOME 434699Amortization, depreciation and financial provisions (311)(306)Interest and similar expenses (789)(790)Foreign exchange loss -(212)Interests on loan (28)(29)Net expense from sales of investments securities (72)(185)TOTAL FINANCIAL EXPENSES (1 200)(1 522) FINANCIAL PROFIT (LOSS) (766)(823) PRE-TAX LOSS (4 254)(12 845)Exceptional income on management operations 3-Exceptional income from previous financial year -63EXCEPTIONAL INCOME 363 EXCEPTIONAL INCOME (LOSS) (23)63Research tax credit -251NET PROFIT & LOSS (4 277)(12 531) Balance sheet June 30, 2024December 31, 2023(in thousands of euros) ASSETS Intangible fixed assets1824Tangible fixed assets1426Financial fixed assets1 7291 805 FIXED ASSETS1 7611 855 Trade receivables and related accounts3 0223 424Other receivables (1)34 98434 324Cash assets7 65411 259Prepaid expenses1 207886 CURRENT ASSETS46 86749 893 Unrealized foreign exchange losses and valuation differences – Assets713Loan redemption premiums9141 218 TOTAL REGULARISATION ACCOUNTS9211 231 TOTAL ASSETS49 54952 979 LIABILITIES Share Capital63550 170Premiums related to share capital532 068529 478Retained earnings(508 438)(537 354)Net loss for the financial year(4 277)(20 881) Total shareholders' equity19 98821 413 Provisions for liabilities713Provisions for charges256700 Total provisions for liabilities and charges263713 Loans and debts from lending institutions20 53620 895Loans and other financial debts3 1564 258Accounts payable and related accounts1 5802 498Tax and social security debts515648Deferred income1 9951 919 Total current liabilities27 78230 218 Unrealized exchange gains1 516635 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY49 54952 979 1 Net revenue consists of revenue from collaborations less royalty payments Attachment EN_H1&Q32024_PR_FINAL

Press Release Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Gross proceeds of $15 million (€13.7 million) for the sale of Nicox’s net share of the VYZULTA royalty to SoleusSoleus investing $1.5 million (€1.37 million) in Nicox shares, issued at €0.3144 per share, representing a 20% premium to the closing price on October 11, 2024, with attached warrants valued at $0.75 million (€0.69 million) at an exercise price of €0.5240 per share, representing a 100% premium to the closing price on October 11, 2024Repayment of €5.2 million of Nicox’s principal debt by June 2025, significantly reducing the Company’s debt burden The Company estimates that this transaction will finance it into Q3 2025Nicox remains a late-stage clinical development company with revenue from ZERVIATE, expected to launch in China shortly, and strong partnerships with Glaukos, Ocumension and KowaTopline results from the NCX 470 Denali Phase 3 trial now expected in Q3 2025 Nicox retains 100% of NCX 470 rights outside the Chinese, Japanese and Southeast Asian markets October 14, 2024 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it has entered into a royalty purchase agreement with Soleus Capital Credit Opportunities Fund I, L.P. (and any affiliated entity, “Soleus”), an investment fund managed by Soleus Capital Management, L.P. (“Soleus Capital”), a US-based life sciences investment firm. Soleus will acquire Nicox’s VYZULTA royalty (net of payments to Pfizer), for $15 million (€13.7 million), together with a subscription of $1.5 million (€1.37 million) for Units comprised of one share with one attached warrant (the “Units”) at €0.3144 per Unit, representing 120% of Nicox's closing share price on 11 October 2024, on the terms set out below. The warrants (the “Warrants”) give the right to acquire a maximum of 1,308,077 Nicox shares at a price of €0.5240 per share, which is a 100% premium to the closing price of Nicox’s ordinary shares on October 11, 2024. Exercise of the warrants would result in additional gross proceeds of €0.69 million. The Company has also entered into agreement with its existing lenders to release the guarantee held over VYZULTA, including, amongst other obligations, the repayment of €5.2 million of outstanding debt by June 2025, as set out below. “VYZULTA was the first nitric oxide donating compound from Nicox’s research to be marketed. The agreements announced today allow us to effectively monetize our VYZULTA revenue stream, creating an immediate source of cash to finance the development of our lead asset, NCX 470, whilst also bringing in a new, specialist investor, investing at a premium, to accompany our future development.” said Gavin Spencer, Chief Executive Officer of Nicox. “In addition, we are able to announce that the accelerated recruitment of patients in the Denali Phase 3 clinical trial of NCX 470 has brought the expected date of topline data into Q3 2025. With our financing needs addressed until Q3 2025, we look forward to the completion of recruitment in the Denali trial, together with the launch of ZERVIATE in China, where it was recently approved, bringing a new revenue stream to the Company.” “We are excited to partner with Nicox on this transaction, providing the company runway towards its key value inflection point of clinical data for its Phase 3 Denali trial. In addition to providing non-dilutive capital in the form of the VYZULTA royalty monetization, we also look forward to accompanying Nicox as shareholders as they continue their work to bring NCX 470 to the market and develop their partnerships,” said Benjamin Lund, Partner at Soleus Capital. Soleus Capital is an investment firm based in Greenwich, CT focused on the innovative areas of life sciences, including biopharmaceuticals, medical technologies, life sciences tools and diagnostics. With approximately $2.2 billion in total assets under management as of October 1, 2024, Soleus Capital invests across the healthcare lifecycle from developmental-stage through commercial, and partners with life science companies across the capital structure. Nicox was advised by Bourne Partners with Lexelians and Farber LLC law firms serving as legal advisors. Soleus was advised by Morgan Lewis & Bockius LLP and Racine. Cash Runway Based on the cash and cash equivalents held by the Company, the net proceeds from the transactions announced today, after deduction of legal, banking and other fees, and expected milestone income from existing agreements, the Company estimates that it is financed into Q3 2025. If any of the assumptions around estimated income, recovery of taxes or costs change, this may impact the cash runway of the Company. The Company continues to evaluate all options for non-dilutive and dilutive financing to extend its cash runway. In particular, the Company is actively exploring multiple strategic options which could facilitate the development and commercialization of its drug candidate NCX 470 and the future growth of the Company. NCX 470 (bimatoprost grenod) Development update NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop, based on the same technology as VYZULTA, and is currently in a second pivotal Phase 3 trial, Denali, in the U.S. and China for the lowering of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. The topline data from the Denali trial is now expected in Q3 2025 and the Company intends to commercialize NCX 470 in the U.S. through a partnership. NCX 470 is already partnered in China and Southeast Asia with Ocumension, who expects to be able to file a Chinese New Drug Application following completion of the Denali trial, and with Kowa in Japan, where additional clinical trials will be required. Upcoming milestones Launch of ZERVIATE in China by Nicox’s partner, Ocumension Therapeutics: Approval announced in September 2024. Whistler Phase 3b clinical trial, initiated in December 2023, investigating NCX 470’s dual mechanism of action (nitric oxide and prostaglandin analog) in intraocular pressure lowering: results are currently expected in Q1 2025. Denali Phase 3 clinical trial evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension: recruitment of the last patient in the U.S. in the Denali trial was announced last July when overall study recruitment was approaching the 95% level. Considering the rate of recruitment in China, topline results are now expected in Q3 2025. The Company cannot guarantee that it is financed to the topline results of the Denali trial, and completion of the Denali trial may require additional financing. About VYZULTA VYZULTA, exclusively licensed worldwide to Bausch + Lomb, is a prostaglandin analog with one of its metabolites being NO. VYZULTA is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension in the U.S. At approval, VYZULTA was the first eye drop approved in the past 20 years with a novel approach to reduce IOP. VYZULTA is commercialized in more than 15 countries, including the U.S. where it is covered by a composition of matter patent to 2029. VYZULTA was licensed exclusively to Bausch + Lomb globally in 2010 and was launched in the U.S. in 2017. Prior to the transaction with Soleus, Nicox received 6% net royalties on global sales, net of royalties payable to Pfizer, per the terms of the contract signed with Pfizer in August 2009, with a $5 million net milestone payable to Nicox at $100 million net sales. Nicox received net royalty revenue of over €4 million in 2023, the majority of which was from VYZULTA sales. Terms of the VYZULTA Royalty Sale to Soleus Under the terms of the agreement, Nicox will receive a payment from Soleus of $15 million (€13.7 million), less certain expenses. In exchange for this payment, Soleus will receive all royalties and milestone payments due to Nicox from VYZULTA sales since 1 July 2024 and in the future, net of payments to Pfizer, per the terms of the contract signed with Pfizer in August 2009. Payments to Pfizer and to Soleus will be made by Bausch + Lomb at the direction of Soleus and Nicox. The agreement includes other customary provisions for a transaction of this nature. The agreement with Soleus only covers VYZULTA revenue and does not include any other Nicox products nor product candidates. In addition to this payment of $15 million Nicox will receive a $1.5 million (€1.37 million) equity financing as detailed below. Terms of the Amendment to the existing Debt Agreement Nicox will make debt repayments of €5.2 million to its existing lender Kreos Capital VI (UK) Limited (together with its affiliates “Kreos”1) by June 2025 and the interest rate on the outstanding debt shall remain at 9.25%. Such repayments will reduce the amortizable portion of the debt, currently representing €11.8 million, out of a total debt with Kreos of €19.4 million. Nicox will also pay a 1% restructuring fee on capital outstanding to Kreos. Kreos will release the security held over VYZULTA and will take an additional security over NCX 470. The other elements of the debt, set out in the Company’s Annual Report 2023, remain unchanged, except as explained below. In addition, Kreos shall be entitled to: 70% of payments for any new license agreements to be offset against amortizable debt.A scaled payment to be made by an acquiror of the company or of significant assets before 31 December 2029 of a minimum of €2 million and which could exceed €5 million if the transaction was over €50 million in value.Additional warrants, potentially exercisable upon certain conditions after repayment of the debt to Kreos, as compensation if the Convertible Debt cannot be converted. Terms of the Capital Increase by Soleus Capital stock before the Transaction Nicox's paid-in capital consists of 64,233,248 fully subscribed and paid-up shares with a par value of €0.01 each. Nature and legal basis of the Transaction Using the authorization granted under the eighth resolution of the Extraordinary Shareholders' Meeting of May 6, 2024, the Company's Board of Directors, meeting on October 11, 2024, voted to make a share capital increase without pre-emptive rights through the issue of Units consisting of shares with attached warrants, in the manner described in this announcement. Number of shares to be issued The total number of Units, each including one share with a par value of €0.01, to be issued is 4,360,256, at a unit subscription price of €0.3144, giving gross proceeds of €1.37 million (representing €43,602.56 of par value plus €1,327,261.93 of new issue premium). Each Unit will carry one Warrant, which is immediately detachable. 10 Warrants will be worth 3 new shares if exercised before 10 October 2034, at the strike price of €0.5240. Exercise of all the warrants would represent additional gross proceeds of around €0.69 million. Subscription price The subscription price for a Unit is €0.3144 i.e. 120% of the closing Nicox share price on October 11, 2024 (€0.2620). Features of the new shares The new shares, which will be subject to all the provisions of the Articles of Association, will be issued with dividend rights. They will be treated in the same way as existing shares as soon as they are issued. Application will be made for the shares to be admitted to trading on Euronext Growth Paris. They will be listed on the same line as existing shares and will be fully equivalent to them as soon as they are admitted to trading. Clearing/settlement and listing of the new shares on Euronext Growth Paris is expected by October 17, 2024. Features of the Warrants The Warrants will be detached from the shares when the Units are issued. The exercise price of the warrants will be €0.5240, i.e 200% of the closing Nicox share price on October 11, 2024 (€0.262), and the warrants may be exercised between October 11, 2024 and October 10, 2034. The warrants will not be listed on Euronext Growth nor any other exchange. 10 Warrants gives the right to 3 shares at the exercise price, which would result in total additional gross proceeds of €0.69 million if all the warrants were exercised. Shareholder structure For your information, to the best knowledge of the Company, the equity and voting rights of the Company, before and after the issuance of 4,360,256 Units, are distributed as follows: ShareholdersBefore transactionAfter completion of the transaction Number of shares % of equity Number of shares% of equity Ocumension3,049,0564.75%3,049,0564.45%HBM Healthcare Investments1,992,6493.10%1,992,6492.91%Soleus--4,360,2566.36%Treasury stock311,0670.48%311,0670.45%Public58,880,47691.67%58,880,47685.84%Total64,233,248100.00 %68,593,504100.00% Impact of the offering on shareholders' equity, per share By way of illustration, the impact of the issue on shareholders' equity per share (calculated on the basis of shareholders' equity at September 30, 2024 and the number of shares in the Company's equity at the same date) would look as follows: Portion of shareholders' equity per share (in €)Undiluted basis*Diluted basis** Before issuing new shares€0.31€0.57After issuing 4,360,256 new shares€0.31€0.56After issuing 4,360,256 new shares and 1,308,077 new shares from exercise of the Warrants€0.32€0.56 * Based on the 64,233,248 shares existing as of September 30, 2024 ** Taking into account the issue of 34,325,201 new shares issuable at the date of this press release on the exercise of stock options (1,655,501 shares), the vesting of restricted stock (1,498,741 shares), the exercise of warrants (17,970,959 shares) and the conversion of bonds convertible into equity (13,200,000 shares). Impact of the transaction on existing shareholders As an example, the impact of the offering on the situation of a shareholder holding 1% of Nicox's common stock prior to the offering (calculated on the basis of the number of shares comprising the Company's common stock on September 30, 2024) would be as follows: Shareholder's % ownershipUndiluted basis*Diluted basis** Before issuing new shares1.00%0.65%After issuing 4,360,256 new shares0.94%0.62%After issuing 4,360,256 new shares and 1,308,077 new shares from exercise of the Warrants0.92%0.62% * Based on the 64,233,248 shares existing as of September 30, 2024 ** Taking into account the issue of 34,325,201 new shares issuable at the date of this press release on the exercise of stock options (1,655,501 shares), the vesting of restricted stock (1,498,741 shares), the exercise of warrants (17,970,959 shares) and the conversion of bonds convertible into equity (13,200,000 shares). Risk factors The Company wishes to alert the public to the risk factors relating to the Company and its activities presented in Section 3 of its 2023 Annual Report, available on the Company's website (www.nicox.com). In particular, the Company is financed through at least February 2025 focusing exclusively on the development of NCX 470. Upon completion of this transaction, the Company estimates that it will be financed through Q3 2025, not counting the possible exercise of the warrants. Notice Inasmuch as the offering is for less than €8 million over a 12-month period, this issue will not require an AMF-approved prospectus. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.com Analyst coverage H.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com Disclaimer This press release and the information it contains does not constitute a sale offer or an offer to subscribe, nor a solicitation to purchase or subscribe Nicox’s shares. This press release is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and the Council of 14 June 2017 (the “Prospectus Regulation”). With respect to the member States of the European Economic Area, other than France (the “Member States”), no action has been undertaken or will be undertaken to make an offer to the public of the shares requiring a publication of a prospectus in one of these Member States. Consequently, the securities cannot be offered and will not be offered in any Member State (other than France) except in accordance with the exemptions set out in Article 1(4) of the Prospectus Regulation, or in other cases which does not require the publication by Nicox of a prospectus pursuant to the Prospectus Regulation and/or applicable regulation in these Member States. This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or any other jurisdiction (other than France). Securities may not be offered or sold in the United States unless they have been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or are exempt from registration. Nicox’s shares have not been and will not be registered under the U.S. Securities Act and Nicox does not intend to make a public offer of its shares in the United States. This press release does not constitute an offer of the securities to the public in the United Kingdom. The distribution of this press release is not made, and has not been approved, by an authorised person within the meaning of Article 21(1) of the Financial Services and Markets Act 2000. Consequently, this press release is directed only at persons who (i) are located outside the United Kingdom, (ii) have professional experience in matters relating to investments and fall within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended and (iii) (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the persons mentioned under (i), (ii) and (iii) referred together as “Relevant Persons”). Nicox’s securities are directed only at Relevant Persons and no invitation, offer or agreements to subscribe, purchase or otherwise acquire the securities of Nicox may be proposed or made other than with Relevant Persons. Any person other than a Relevant Person may not act or rely on this document or any provision thereof. This press release is not a prospectus which has been approved by the Financial Conduct Authority or any other United Kingdom regulatory authority for the purposes of Section 85 of the Financial Services and Markets Act 2000. This press release contains indications on the targets of Nicox as well as forward-looking statements. This information is not historical data and shall not be interpreted as a guarantee that the facts and data announced will occur. Such information is based on data, hypothesis and assumptions considered to be reasonable by Nicox. The Company operates in a constantly changing competitive environment. Therefore, it cannot anticipate all risks, uncertainties or other factors that may have an impact on its business, nor the extent to which the occurrence of a risk or combination of risks may have materially different outcomes to those referred to in any forward-looking information. Such information is valid only at the date of the present press release. Nicox does not commit, in any way, to publish updates on the information nor on the hypothesis on which they are based except in cases where it has a legal or regulatory requirement to do so. Risk factors that could have a significant impact on Nicox's business are described in section 3 of the 2024 Annual Report, which is available on Nicox's website (www.nicox.com). The distribution of this press release in certain countries may be subject to a specific regulation. Consequently, persons present in such countries and in which the press release is disseminated, published, or distributed shall comply to such laws and regulations. The information contained in this document does not constitute an offer of securities for sale in the United States of America, Canada, Australia or Japan. This press release may not be published, forwarded, or distributed, directly or indirectly, in the United States, Canada, Australia or Japan. Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 1 BlackRock Inc. announced the completion of its acquisition of Kreos, a leading provider of growth and venture debt financing to companies in the technology and healthcare industries, on 2 August 2023. Attachment EN_SoleusFinancing_PR_FINAL

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. AGC Biologics said it is laying off a total of 95 staffers, which will be effective from November. The manufacturing company is cutting 80 workers in Colorado, 63 of whom are in Longmont and 17 are in Boulder. Another 10 staffers will be cut in Bothell, WA. The company’s Longmont factory will remain “partially open,” according to a WARN notice published last week. Lonza has become the third publicly announced manufacturer to make Vertex Pharmaceuticals’ Casgevy, according to a Tuesday release. Lonza will make commercial Casgevy at its facility in Geleen, the Netherlands, with plans to also make it in Portsmouth, NH, in 2025. RoslinCT and Charles River Laboratories are the other two companies previously tapped by Vertex to make the gene therapy. Eurofins CDMO Alphora is building a new 50,000 square foot facility to manufacture monoclonal antibodies and protein-based therapies, the company said Tuesday. The new site at Eurofins’ Sheridan Research Park campus in Ontario will open in April 2026. The Canadian government has contributed $64.1 million to help Eurofins build the factory. Bavarian Nordic has secured $63 million from the Biomedical Advanced Research and Development Authority to manufacture its smallpox and mpox vaccine Jynneos. The vaccines will be manufactured next year for rollout in 2026, according to a Tuesday announcement. Thermo Fisher Scientific is expanding its factories in Cincinnati, OH, and Bend, OR, to boost its oral solid dose manufacturing capacity. The facility in Bend will double its footprint and house R&D manufacturing and testing for oral solid doses, the company said Thursday. Legend Biotech will evaluate Multiply Labs’ robotic technology in its potential to manufacture cell therapies, the companies announced Tuesday. Capricor Therapeutics has established internal commercial manufacturing for its Duchenne muscular dystrophy cardiomyopathy asset named deramiocel. The company is planning to submit a biologics license application to the FDA in October, the company said Tuesday. Private equity firm Blue Wolf Capital Partners has completed its acquisition of seven manufacturing facilities in Europe from the CDMO Recipharm, according to a Wednesday release. The acquisition was first announced in April. Ophthalmic pharma company Harrow is expanding its headquarters in Nashville and will hire an additional 150 people, the company said Wednesday. Lonza has extended its collaboration with Acumen Pharmaceuticals to manufacture the Phase 2 asset sabirnetug, which is being investigated for Alzheimer’s disease, the companies said Thursday. Acumen originally tapped Lonza to make sabirnetug in April. CDMO SK pharmteco and supply chain logistics company Cryoport announced a new partnership Wednesday. Cryoport will handle SK pharmteco’s supply chains for small molecules and cell and gene therapies, including shipping and collecting materials.